

IssuerPursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934For the quarterly period ended December 31, 2024 Commission File Number 001-38332Â \_\_\_\_\_ QIAGEN N.V.(Translation of registrantâ€™s name into English)Â \_\_\_\_\_ Hulsterweg 825912 PL VenloThe Netherlands (Address of principal executive offices)Â \_\_\_\_\_ Indicate by checkmark

Netherlands(Address of principal executive office) A \_\_\_\_\_ A Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Â· Form 40-F Â· 01Table of ContentsQIAGEN N.V. Form 6-KTABLE OF CONTENTSÂ· ItemPageOther Information3Signatures4Exhibit Index52Table of ContentsOTHER INFORMATIONOn February 5, 2025, QIAGEN N.V. (NYSE: QGEN; Frankfurt, Prime Standard: QIA) issued a press release announcing its unaudited financial results for the fourth quarter and year ended DecemberÂ· 31, 2024. The press release is furnished herewith as Exhibit 99.1 and is incorporated by reference herein.QIAGEN has regularly reported adjusted results, which are considered non-GAAP financial measures, to give additional insight into our financial performance as a supplement to understand, manage, and evaluate our business results and make operating decisions. We also use the adjusted results when comparing to our historical operating results, which have consistently been presented on an adjusted basis.Adjusted results should be considered in addition to the reported results prepared in accordance with U.S. generally accepted accounting principles, but should not be considered as a substitute. Reconciliations of reported results to adjusted results are included in the tables accompanying the press release. We believe certain items should be excluded from adjusted results when they are outside of our ongoing core operations, vary significantly from period to period, or affect the comparability of results with the Companyâ€™s competitors and our own prior periods.The non-GAAP financial measures used in this press release are non-GAAP net sales, gross profit, operating income, pre-tax income, net income, tax rate and diluted earnings per share. These adjusted results exclude costs related to business integration, acquisition and restructuring related items, long-lived asset impairments, amortization of acquired intangible assets, non-cash interest expense charges as well as other special income and expense items. Management views these costs as not indicative of the profitability or cash flows of our ongoing or future operations and therefore considers the adjusted results as a supplement, and to be viewed in conjunction with, the reported GAAP results. We use a measure of free cash flow to estimate the cash flow remaining after purchases of property, plant and equipment as required to maintain or expand our business. This measure provides us with supplemental information to assess our liquidity needs. We calculate free cash flow as net cash from operating activities less purchases of property, plant and equipment.We also consider results on a constant currency basis. Our functional currency is the U.S. dollar and our subsidiariesâ€™ functional currencies are the local currency of the respective countries in which they are headquartered. A significant portion of our revenues and expenses is denominated in euros and currencies other than the United States dollar. Management believes that analysis of constant currency period-over-period changes is useful because changes in exchange rates can affect the growth rate of net sales and expenses, potentially to a significant degree. Constant currency figures are calculated by translating the local currency actual results in the current period using the average exchange rates from the previous yearâ€™s respective period instead of the current period.We use non-GAAP and constant currency financial measures internally in our planning, forecasting and reporting, as well as to measure and compensate our employees. We do not reconcile forward-looking non-GAAP financial measures to the corresponding GAAP measures due to the high variability and difficulty in making accurate forecasts and projections that are impacted by future decisions and actions. Accordingly, reconciliations of these forward-looking non-GAAP financial measures to the corresponding GAAP measures are not available without unreasonable effort. However, the actual amounts of these excluded items will have a significant impact on QIAGENâ€™s GAAP results.3Table of ContentsSIGNATURESPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.Â· QIAGEN N.V. By:/s/ Roland SackersÂ· Roland SackersÂ· Chief Financial OfficerDate: February 6, 20254Table of ContentsEXHIBIT

RELEASEREGION: North America  
RELEASE DATE: February 5, 2025  
EXHIBIT NUMBER: 99.1  
EXHIBIT DESCRIPTION: Press Release  
RELEASED BY: QIAGEN N.V.  
EXHIBIT 99.1  
QIAGEN delivers solid Q4 2024 growth ahead of outlook. Net sales of \$521 million (+2% actual rates, +4% constant exchange rates (CER) core growth); diluted EPS of \$0.39 and adjusted diluted EPS of \$0.61. Net sales of \$525 million CER ahead of outlook for at least \$520 million CER and adjusted diluted EPS of \$0.61 CER ahead of outlook for at least \$0.60 CER. QIAstat-Dx, QuantiFERON and QIAcuity digital PCR continue double-digit growth pace (30.6% adj. operating income margin up 2.6 percentage points vs. 28.0% in Q4 2023). FY 2024: Exceeded outlook for sales and adj. EPS; adj. operating income margin improves 1.8 percentage points to 28.7%. Free cash flow rises 63% to \$506 million. 2025 outlook for about 4% CER sales growth (about +5% CER core sales growth) and adj. diluted EPS of at least \$2.28 CER; targeting adj. operating income margin improvement of at least 150 basis points.  
VENLO, the Netherlands, February 5, 2025 - QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced financial results for the fourth quarter and full-year 2024. Net sales for Q4 2024 increased 2% to \$521 million compared to Q4 2023, while sales at constant exchange rates (CER) of \$525 million rose 3% and were above the outlook for at least \$520 million CER and core sales (excluding discontinued products such as NeuMoDx and Dialunox) rose 4% CER. The adjusted operating income margin improved by 2.6 percentage points to 30.6%, driven by efficiency gains and benefits from the NeuMoDx decision, enabling reinvestments into targeted growth initiatives. Adjusted diluted earnings per share (EPS) were \$0.61, and CER results of \$0.61 were above the outlook for at least \$0.60 CER. QIAGEN expects the solid growth pace in H2 2024 to continue in 2025. Net sales are expected to rise about 4% CER (and core sales growth of about 5% CER). Adjusted diluted EPS is expected to be at least \$2.28 CER, driven by a goal to improve the adjusted operating income margin by at least 150 basis points to above 30% while absorbing lower non-operating income contributions than in 2024. "Our teams at QIAGEN concluded 2024 with a solid performance in the fourth quarter, exceeding our outlook for net sales and profitability. These results underscore the resilience of our portfolio, with over 85% of sales coming from highly recurring revenues, and our focus on delivering solid profitable growth in an ongoing challenging environment," said Thierry Bernard, CEO of QIAGEN. "Our solid sales growth in the second half of 2024 mirrors our plans for further strong growth in 2025 as we reconfirm our 2028 targets. QIAstat-Dx exceeded expectations with four FDA clearances for our syndromic testing system in 2024 and one already in 2025, coupled with over 660 placements in 2024 that was ahead of our target. QuantiFERON delivered 11% CER growth for 2024, with significant opportunities for further expansion since only 40% of the global latent TB testing market has so far been converted from the outdated skin test. QIAcuity also delivered solid growth despite challenging instrument purchase trends as we expanded digital PCR into clinical use in 2024 while expanding our presence with academia, research institutions and healthcare providers. We are well-positioned to continue our growth trajectory in 2025 and beyond."

pharma and other customers."1"We are pleased with our 2024 results that featured strong free cash flow combined with solid sales growth and a significant increase in the outlook for adjusted EPS during the year thanks to operational profitability improvements. Our confidence in QIAGEN's future is reflected in the return of about \$300 million to shareholders in January through a synthetic share repurchase. We remain well-positioned to execute on our 2028 commitments for solid profitable growth, supported by our differentiated portfolio and disciplined capital allocation that seeks to strengthen our business while increasing returns to shareholders," said Roland Sackers, CFO of QIAGEN. Key figuresIn \$ millions(Except EPS and diluted shares)Q4FY20242023Change20242023ChangeNet

sales521Â 509Â 2Â %1,978Â 1,965Â 1Â %Net sales - CER525Â 3Â %1,991Â 1Â %Operating income119Â 111Â 8Â %98Â 410Â -76Â %Net income88Â 98Â -10Â %84Â 341Â -76Â %Diluted

EPS\$0.39Â \$0.42Â -7Â %\$0.37Â \$1.48Â -75Â %Diluted shares (in millions)224231225231Adjusted operating income159Â 142Â 12Â %567Â 529Â 7Â %Adjusted net income136Â 127Â 7Â %491Â 477Â 3Â %Adjusted diluted EPS\$0.61Â \$0.55Â 11Â %\$2.18Â \$2.07Â 5Â %Adjusted diluted EPS - CER\$0.61Â 11Â %\$2.20Â 6Â %Please refer to accompanying tables in this release for full income statement information and a reconciliation of reported to adjusted figures. Tables may have rounding differences. Percentage changes are to prior-year periods. â€¢Sales: Q4 2024 results showed 3% CER sales growth compared to Q4 2023, and 4% CER core growth (excluding sales from discontinued products). Diagnostic solutions led the product groups with 10% CER growth (+12% core growth) and driven by QuantiFERON (+14% CER) and QIAstat-Dx (+25% CER). PCR and Genomics product groups also delivered higher sales, while Sample technologies saw a modest decline. Consumables and related revenues grew 4% CER over Q4 2023, while instrument sales declined 6% CER due to ongoing cautious customer capital spending trends throughout 2024. For FY 2024, net sales increased 1% CER - and core sales rose 2% CER - supported by improving growth trends in H2 2024 compared to results in H2 2023. â€¢Operating income: In Q4 2024, operating income rose 8% to \$119 million, and included \$21 million of pre-tax charges related to ongoing efficiency measures including the discontinuation of NeuMoDx. Adjusted operating income increased 12% to \$159 million, with the adjusted operating income margin improving to 30.6% of sales from 28.0% in Q4 2023. This was driven by efficiency gains across QIAGEN that enabled reinvestments into growth initiatives, along with benefits of the NeuMoDx decision. In terms of components, the adjusted gross margin rose to 67.1% of sales from 65.7% in Q4 2023 due to various factors such as higher production capacity utilization. R&D investments were 9.3% of sales in Q4 2024, up slightly from 9.0% in Q4 2023, and aligned with the FY 2024 target. Sales and marketing expenses decreased to 21.8% of sales from 23.1% in Q4 2023, while General and administrative expenses declined to 5.3% of sales from 5.6% in Q4 2023. For FY 2024, the adjusted operating income margin was 28.7% of sales, an increase of 1.8 percentage points from 26.9% in 2023. â€¢EPS: Diluted EPS was \$0.39 per share in Q4 2024 compared to \$0.42 in Q4 2023. Adjusted diluted EPS for Q4 2024 were \$0.61 (\$0.61 CER), and above the outlook for at least \$0.60 CER. The adjusted tax rate was 19% in Q4 2024, and consistent with the quarterly estimate. For FY 2024, adjusted diluted EPS increased to \$2.18 (\$2.20 CER) from \$2.07 in 2023, reflecting the significant improvements in adjusted operating income during the course of the year compared to the initial outlook for at least \$2.10 CER.2Sales by product groupsIn \$ millionsQ4FY2024sales2023salesChangeCER change2024sales2023salesChangeCER changeSample

technologies162Â 164Â -2Â %-1Â %642Â 663Â -3Â %-3Â %Diagnostic

solutions196Â 180Â +9Â %+10Â %749Â 698Â +7Â %+8Â %Of which

QuantiFERON116Â 102Â +13Â %+14Â %454Â 408Â +11Â %+11Â %Of which QIAstat-Dx32Â 26Â +25Â %+25Â %109Â 88Â +24Â %+24Â %Of which

NeuMoDx9Â 11Â -19Â %-19Â %32Â 42Â -24Â %-24Â %Of which Other40Â 41Â -2Â %-2Â %154Â 159Â -3Â %-2Â %PCR / Nucleic acid amplification82Â 81Â +2Â %+3Â %300Â 300Â 0Â %+1Â %Genomics /

NGS66Â 65Â +1Â %+2Â %234Â 239Â -2Â %-1Â %Other15Â 19Â -24Â %-21Â %53Â 66Â -19Â %-15Â %Total net sales521Â 509Â +2Â %+3Â %1,978Â 1,965Â +1Â %+1Â %Tables may have rounding differences. Percentage changes are to prior-year periods.â€¢Sample technologies: Higher sales of consumables for use on QIAGEN instruments, as well as for Human ID / Forensics applications, led the performance in Q4 2024. The EZ2 Connect system reached a milestone of over 1,000 cumulative placements since launch. Overall sales were slightly lower than in Q4 2023 due to a modest sales decline in manual kits and challenging instrument sales trends that continued throughout 2024.â€¢

Diagnostic solutions: Q4 2024 sales grew 10% CER, and rose 12% CER excluding NeuMoDx, led by double-digit CER gains in consumables sales that absorbed a decline in instrument sales over Q4 2023. The QuantiFERON test for latent tuberculosis (TB) detection delivered 14% CER sales growth on solid demand in all regions as only about 40% of the global latent TB testing market has been converted to blood-based testing. QIAstat-Dx delivered 25% CER sales growth on double-digit gains in both consumables and instruments. The syndromic testing system surpassed the 2024 goal with over 660 new placements and reached more than 4,600 cumulative placements since launch. The NeuMoDx system remains on track for discontinuation in mid-2025.â€¢PCR / Nucleic acid amplification: Q4 2024 sales rose 3% CER over the year-ago period driven by the QIAcuity digital PCR system, which saw double-digit CER growth in consumables and reached over 2,700 cumulative placements since launch despite ongoing challenging instrument purchasing trends. Sales of other PCR consumables grew at a low single-digit CER rate compared to Q4 2023.â€¢Genomics / Next-generation sequencing (NGS): Sales for Q4 2024 grew 2% CER over Q4 2023, supported by growth in universal consumables used on third-party NGS systems. QIAGEN Digital Insights (QDI) sales increased at a single-digit CER rate, driven by growth in the clinical portfolio that more than offset a modest decline in the discovery portfolio. QDI's results in 2024 were adversely impacted by the ongoing transition to SaaS (software-as-a-service) subscription models, particularly in the pharmaceutical sector, from longer-term licensing agreements.3Key cash flow dataIn \$ millionsQ4FY20242023ChangeNet cash provided by operating

activities192Â 151Â +27Â %674Â 459Â +47Â %Purchases of property, plant and equipment(49)(52)-5Â %(167)(150)+12Â %Free cash flow142Â 100Â +43Â %506Â 310Â +63Â %Net cash used in investing activities(7)(59)NM(249)(88)NMNet cash used in financing activities(489)(8)NM(423)(434)NMTables may have rounding differences. Percentage changes are to prior-year periods.â€¢Net cash from operating activities was \$674 million in 2024, a 47% increase from \$459 million in 2023 that reflected reduced working capital requirements and a strong focus on cash flow optimization. Free cash flow rose 63% to \$506 million in 2024, absorbing a slight increase in investments into property, plant and equipment.â€¢As of DecemberÂ 31, 2024, cash, cash equivalents and short-term investments were \$1.2 billion compared to \$1.1 billion at the end of 2023. Key cash flow activities in 2024 included the repayment of \$500 million in convertible notes that matured in November, net proceeds of \$494.2 million from the issuance of new convertible notes in September, the return of approximately \$300 million in January through a synthetic share repurchase and the repayment of \$101.5 million of German private debt placements in June. The leverage ratio declined

to 0.3x (net debt to adjusted EBITDA) as of December 31, 2024 compared to 0.6x at the end of 2023, but increased to 0.7x after completion of the approximately \$300 million synthetic share repurchase in January 2025. Portfolio update QIAGEN is accelerating momentum in its Sample to Insight portfolio through targeted developments: QIAstat-Dx: The QIAstat-Dx Gastrointestinal Panel Mini B&V (bacterial and viral) has received U.S. regulatory clearance, supporting outpatient diagnostics for gastrointestinal conditions. This panel detects five common bacterial and viral causes of gastrointestinal illnesses. A second version for outpatient use with five targets focused exclusively on bacterial infections is planned to soon be submitted for FDA clearance. Additionally, the QIAstat-Dx Rise system has also recently been submitted for FDA clearance, building on the launch of this higher-throughput system in Europe in 2022. These developments build on the FDA clearance of four QIAstat-Dx panels in 2024, enabling QIAGEN to offer a comprehensive menu of tests in the U.S. for diagnosis of respiratory, gastrointestinal and meningitis / encephalitis conditions. QIAcuity digital PCR: This breakthrough system now supports multiplexing of up to 12 targets from a single sample, up from the previous limit of five. This enhancement, which requires no hardware changes, was enabled by the recent release of QIAcuity Software 3.1 and the new QIAcuity High Multiplex Probe PCR Kit. These innovations help provide deeper insights for translational research, microbiome analysis, pathogen detection as well as for novel cell and gene therapies. Sample technologies: QIAGEN has surpassed a milestone of over 1,000 placements of the EZ2 Connect automated sample preparation instrument. This versatile platform supports kits to gain DNA and RNA from a wide range of sample types, opening up possibilities for downstream applications involving diagnostics, genomics and cancer as well as epidemiology and forensics.

Companion diagnostics: QIAGEN recently received FDA approvals for two new companion diagnostic tests to help guide treatment decisions, expanding the portfolio to 16 FDA-approved companion diagnostic tests based on the PCR technology. The therascreen KRAS RGQ PCR Kit was approved for use in identifying patients with metastatic colorectal cancer eligible for Amgen's Lumakras (sotorasib) in combination with Vectibix (panitumumab), and the therascreen BRAF V600E RGQ PCR Kit was approved for use with Array Biopharma's Braftovi (encorafenib) in patients with metastatic melanoma. QIAGEN Digital Insights (QDI): The QDI portfolio has been enhanced with new Artificial Intelligence features through a new AI extension for its Ingenuity Pathway Analysis (IPA). This software helps distill complex differential expression analyses into actionable insights. Additionally, QIAGEN is collaborating with Genomics England on the Generation Study, which aims to sequence the genomes of 100,000 newborns to screen for over 200 selected genetic conditions. The QIAGEN Clinical Knowledge Base contributes clinically relevant variant content for genes included in the point-of-care sequencing test, enabling rapid variant interpretation and reporting. QIAGEN completes return of about \$300 million to shareholders In January 2025, QIAGEN completed the return of about \$300 million to shareholders through a synthetic share repurchase. This follows a similar return of about \$300 million at the start of 2024 as part of a commitment to return at least \$1 billion to shareholders between 2024 and the end of 2028. This type of repurchase, which combines a direct capital repayment with a reverse stock split, offers a more efficient way to return cash to shareholders than an open-market repurchase while also enhancing earnings per share through a reduction in the number of shares outstanding. Evolving the QIAGEN organization As part of the QIAefficiency initiative launched in 2024 to simplify and improve operations, QIAGEN reorganized its global structure as of January 2025 by transforming its three Business Areas - Molecular Diagnostics, Life Sciences and QIAGEN Digital Insights - into two new global functional teams. The Product Portfolio & Innovation team, led by Nitin Sood, will integrate functions spanning Global Marketing, Clinical Medical Regulatory Affairs, R&D and Product Management. The Commercial Operations team, led by Fernando Beils, will unify and strengthen QIAGEN's sales and regional marketing teams. Both leaders will continue to serve on the Executive Committee. Outlook For 2025, QIAGEN has initiated an outlook that anticipates a continuation of the solid growth trends from H2 2024. Net sales are expected to rise about 4% CER (about 5% CER in the core business).

Adjusted diluted EPS is expected to be at least \$2.28 CER, supported by a goal to improve the adjusted operating income margin by at least 150 basis points to above 30% while absorbing lower non-operating income contributions and a higher adjusted tax rate than in 2024. For Q1 2025, net sales are expected to rise about 3% CER (about 4% CER in the core business) from \$459 million in Q1 2024. Adjusted diluted EPS are expected to be at least \$0.50 CER compared to \$0.46 in Q1 2024. Based on exchange rates as of February 1, 2025, for FY 2025, currency movements against the U.S. dollar are expected to have a negative impact on net sales of about two percentage points and a negative impact of about \$0.02-\$0.03 per share on adjusted EPS results. For Q1 2025, currency movements against the U.S. dollar are expected to have a negative impact on net sales of about two percentage points and a negative impact of about \$0.01 per share on adjusted EPS results. Investor presentation and conference call A conference call is scheduled for Thursday, February 6, 2025, at 16:00 Frankfurt Time / 15:00 London Time / 10:00 New York Time. A live audio webcast will be accessible in the investor relations section of the QIAGEN website ([www.qiagen.com](http://www.qiagen.com)), with a recording available after the event. The presentation will be published ahead of the call in this section: QIAGEN Investor Relations - Events and Presentations. Use of adjusted results QIAGEN reports adjusted results, as well as results on a constant exchange rate (CER) basis, along with other non-U.S. GAAP (generally accepted accounting principles) measures, to provide deeper insights into its performance. These include metrics such as core sales (excluding discontinued products), adjusted gross margin, adjusted gross profit, adjusted operating income, adjusted operating expenses, adjusted operating income margin, adjusted net income, adjusted net income before taxes, adjusted diluted EPS, adjusted EBITDA, adjusted EPS, adjusted income taxes, adjusted tax rate, and free cash flow. Free cash flow is calculated by subtracting capital expenditures for property, plant and equipment from cash flow from operating activities. Adjusted results are non-GAAP financial measures that QIAGEN considers complementary to GAAP-reported results but not as substitutes. These measures exclude items that QIAGEN believes are outside of ongoing core operations, fluctuate significantly between periods, or hinder the comparability of results with competitors and prior periods. QIAGEN also uses non-GAAP and constant currency financial measures internally in planning, forecasting and reporting, and also for employee compensation. Additionally, adjusted results are used to compare current performance with historical results, which have consistently been presented on an adjusted basis. About QIAGEN QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions, enabling customers to extract and gain valuable molecular insights from samples containing the building blocks of life. Our Sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies prepare these biomolecules for analysis while bioinformatics software and knowledge bases can be used to interpret data to find actionable insights. Automation solutions bring these processes together into seamless and cost-effective workflows. QIAGEN serves over 500,000 customers globally in Life Sciences (academia, pharma R&D and industrial applications, primarily forensics) and Molecular Diagnostics for clinical healthcare. As of December 31, 2024, QIAGEN employed more than 5,700 people in over 35 locations worldwide. For more information, visit [www.qiagen.com](http://www.qiagen.com). Forward-Looking Statement

Certain statements in this press release may constitute forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. These statements, including those regarding QIAGEN's products, development timelines, marketing and / or regulatory approvals, financial and operational outlook, growth strategies, collaborations and operating results - such as expected adjusted net sales and adjusted diluted earnings - are based on current expectations and assumptions. However, they involve uncertainties and risks. These risks include, but are not limited to, challenges in managing growth and international operations (including the effects of currency fluctuations, regulatory processes and logistical dependencies), variability in operating results and allocations between customer classes, commercial development for our products to customers in the Life Sciences and clinical healthcare, changes in relationships with customers, suppliers or strategic partners; competition and rapid technological advancements; fluctuating demand for QIAGEN's products due to factors such as economic conditions, customer budgets and funding cycles; obtaining and maintaining regulatory approvals for our products; difficulties in successfully adapting QIAGEN's products into integrated solutions and producing these products; and protecting product differentiation from competitors. Additional uncertainties may arise from market acceptance of new products, integration of acquisitions, governmental actions, global or regional economic developments, natural disasters, political or public health crises, and other "force majeure" events. There is also no guarantee that anticipated benefits from acquisitions will materialize as expected. For a comprehensive overview of risks, please refer to the "Risk Factors" contained in our most recent Annual Report on Form 20-F and other reports filed with or furnished to the U.S. Securities and Exchange Commission.

6 Contacts Investor Relations Public Relations John Gilardi +49 152 018 11711 Thomas Theuringer +49 2103 29 11826 Domenica Martorana +49 152 018 11244 Lisa Specht +49 2013 29 14181 e-mail: ir@QIAGEN.com e-mail:

pr@QIAGEN.com 7 QIAGEN N.V. CONDENSED CONSOLIDATED STATEMENTS OF INCOME (unaudited) (In \$ thousands, except per share data) Three months ended December 31, 2024 2023 2024 2023 Net sales \$521,202 \$509,162 \$1,978,214 \$1,965,311 Cost of sales: Cost of sales 174,401 177,018 952,323 667,425 Acquisition-related intangible amortization 13,511 16,044 58,541 64,198 Total cost of sales 187,912 193,062 1,010,864 731,623 Gross profit 333,290 316,100 967,350 1,233,688 Operating expenses: Sales and marketing 113,860 117,478 450,929 459,912 Research and development 48,605 45,966 193,494 198,511 General and administrative 27,852 28,474 113,432 119,254 Acquisition-related intangible amortization 1,809 2,692 9,596 10,764 Restructuring, acquisition, integration and other, net 22,066 10,875 102,188 35,309 Total operating expenses 214,192 205,485 869,639 823,750 Income from operations 119,098 110,615 97,711 409,938 Other income (expense): Interest income 15,092 19,261 68,016 78,992 Interest expense (11,143) (12,441) (43,841) (53,410) Other income (expense), net 2,805 1,441 (739) (5,711) Total other income, net 6,754 8,261 23,436 19,871 Income before income tax expense 125,852 118,876 121,147 429,809 Income tax expense 37,530 21,212 37,556 88,506 Net income \$88,322 \$97,664 \$83,591 \$341,303 Diluted earnings per common share \$0.39 \$0.42 \$0.37 \$1.48 Diluted earnings per common share (adjusted) \$0.61 \$0.55 \$2.18 \$2.07 Diluted shares used in computing diluted earnings per common share 224,245 230,745 224,717 230,619 QIAGEN N.V. RECONCILIATION OF REPORTED TO ADJUSTED RESULTS (In \$ millions, except EPS data) (unaudited) Three months ended December 31, 2024 Net Sales Gross Profit Operating Income Pre-tax Income Income Tax Tax Rate Net Income Diluted EPS \* Reported results 521.2 333.2 119.1 125.8 (37.5) 30 % 88.3 \$0.39 Adjustments: Business integration, acquisition and restructuring related items (a) 3.0 25.1 25.1 (4.6) 20.5 0.09 Purchased intangibles amortization 13.5 15.3 15.3 (3.8) 11.5 0.05 Non-cash interest expense charges (b) 2.4 2.4 2.4 0.01 Non-cash other income, net (c) 0.5 0.5 0.5 0.00 Certain income tax items (d) 13.2 13.2 0.06 Total adjustments 16.6 40.3 43.3 4.8 48.1 0.22 Adjusted results 521.2 349.8 159.4 169.1 (32.7) 19 % 136.4 \$0.61 \* Using 224.2 M diluted shares

Twelve months ended December 31, 2024 Net Sales Gross Profit Operating Income Pre-tax Income Income Tax Tax Rate Net Income Diluted EPS \* Reported results 1,978.2 967.3 97.7 121.1 (37.5) 31 % 83.6 \$0.37 Adjustments: Business integration, acquisition and restructuring related items (a) 298.9 401.1 401.1 (78.6) 322.5 1.44 Purchased intangibles amortization 58.5 68.1 68.1 (16.8) 51.3 0.23 Non-cash interest expense charges (b) 17.0 17.0 17.0 0.08 Non-cash other income, net (c) 3.1 3.1 0.01 Certain income tax items (d) 13.2 13.2 0.06 Total adjustments 357.5 469.3 489.4 (82.2) 407.2 1.81 Adjusted results 1,978.2 1,324.8 567.0 610.5 (119.7) 20 % 490.8 \$2.18 \* Using 224.7 M diluted shares (a) Includes costs incurred in connection with streamlining operations and improving overall efficiency as well as costs related to various contemplated and completed acquisition projects and their subsequent integration. (b) Cash Convertible Notes were recorded at an original issue discount that is recognized as incremental non-cash interest expense over the expected life of the notes. (c) Adjustment includes the net impact of changes in fair value of the Call Options and the Embedded Cash Conversion Options related to the Cash Convertible Notes. (d) These items represent updates in QIAGEN's assessment of ongoing examinations or other tax items that are not indicative of the Company's normal future income tax expense. Tables may contain rounding differences.

9 QIAGEN N.V. CONDENSED CONSOLIDATED BALANCE SHEETS (In \$ thousands, except par value) December 31, 2024 December 31, 2023 Assets (unaudited) Current assets: Cash and cash equivalents \$663,555 \$668,084 Short-term investments 489,437 389,698 Accounts receivable, net 349,278 381,877 Inventories, net 279,256 398,385 Prepaid expenses and other current assets 178,327 309,516 Total current assets 1,959,853 2,147,560 Long-term assets: Property, plant and equipment, net 753,611 765,037 Goodwill 2,425,418 2,475,732 Intangible assets, net 303,815 526,821 Other long-term assets 246,925 200,040 Total long-term assets 3,729,769 3,967,630 Total assets \$5,689,622 \$6,115,190 Liabilities and equity: Current liabilities: Current portion of long-term debt \$53,481 \$587,970 Accrued and other current liabilities 406,876 407,168 Accounts payable 83,272 84,155 Total current liabilities 543,629 1,079,293 Long-term liabilities: Long-term debt, net of current portion 1,338,067 921,824 Other long-term liabilities 240,587 306,309 Total long-term liabilities 1,578,654 1,228,133 Equity: Common shares, 0.01 EUR par value, authorized 410,000 shares, issued 223,904 and 230,829 shares, respectively 2,601 2,702 Additional paid-in

capital1,666,070Â 1,915,115Â Retained earnings2,448,122Â 2,456,800Â Accumulated other comprehensive loss(474,539)(433,830)Less treasury stock, at cost â€" 1,614 and 2,627 shares, respectively(74,915)(133,023)Total equity3,567,339Â 3,807,764Â Total liabilities and equity\$5,689,622Â \$6,115,190Â 10QIAGEN N.V. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(In \$ thousands)Twelve Months Ended December 31,20242023Cash flows from operating activities:(unaudited)Net income\$83,591Â \$341,303Â Adjustments to reconcile net income to net cash provided by operating activities, net of effects of businesses acquired:Depreciation and amortization203,268Â 205,336Â Non-cash impairments203,408Â 4,158Â Amortization of debt discount and issuance costs18,428Â 30,162Â Share-based compensation expense43,627Â 47,100Â Deferred tax (benefit) expense(23,041)10,731Â Other items, net including fair value changes in derivatives8,817Â 7,623Â Change in operating assets, net113,013Â (94,825)Change in operating liabilities, net22,440Â (92,133)Net cash provided by operating activities673,551Â 459,455Â Cash flows from investing activities:Purchases of property, plant and equipment(167,174) (149,710)Purchases of intangible assets(4,068)(13,092)Purchases of short-term investments(685,915) (976,448)Proceeds from redemptions of short-term investments584,979Â 1,270,551Â Cash paid for acquisitions, net of cash acquiredâ€"Â (149,532)Cash received (paid) for collateral asset25,414Â (66,583)Purchases of investments, net(2,465)(2,870)Other investing activitiesâ€"Â 29Â Net cash used in investing activities(249,229)(87,655)Cash flows from financing activities:Proceeds from long-term debt, net of issuance costs494,211Â â€"Â Repayment of long-term debt(601,536)(400,000)Capital repayment(292,099)â€"Â Proceeds from exercise of call options related to cash convertible notesâ€"Â 36,762Â Payment of intrinsic value of cash convertible notesâ€"Â (36,762)Tax withholding related to vesting of stock awards(34,160)(17,675)Cash received (paid) for collateral liability11,350Â (16,315)Other financing activities(662)163Â Net cash used in financing activities(422,896)(433,827)Effect of exchange rate changes on cash and cash equivalents(5,955)(558)Net decrease in cash and cash equivalents(4,529)(62,585)Cash and cash equivalents, beginning of period668,084Â 730,669Â Cash and cash equivalents, end of period\$663,555Â \$668,084Â Reconciliation of free cash flow(1)Net cash provided by operating activities\$673,551Â \$459,455Â Purchases of property, plant and equipment(167,174)(149,710)Free cash flow\$506,377Â \$309,745Â (1) Free cash flow is a non-GAAP financial measure and is calculated from net cash provided by operating activities reduced by purchases of property, plant and equipment. 11